Search clinical trials for: Rituximab sc

Total 3599 results

Royal College of Surgeons, Ireland
Health Service Executive

Unknown

Creating a Proficiency-Based Virtual Reality Simulation Training Programme for Laparoscopic Assisted Colectomy (LAC)

Colorectal Disease

United Kingdom, Ireland
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
McMaster University
Heart and Stroke Foundation of Ontario

Completed

Fixed Dose Heparin Study

Deep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism

Canada, New Zealand
Craig L Slingluff, Jr
GlaxoSmithKline

Completed

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (Mel55)

Melanoma

United States
University Hospital, Rouen

Not yet recruiting

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus (RITUX4)

Pemphigus | Dermatologic Disease
Byondis B.V.

Recruiting

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Lymphoma

Spain, United Kingdom, Netherlands, Italy
Epizyme, Inc.
Swedish Cancer Institute

Terminated

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Grupo Español de Linfomas y Transplante Autólogo...

Unknown

Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT (MAN2)

Mantle-cell Lymphoma

Spain
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) (Z-RIC-Allo)

Non-Hodgkin Lymphoma

Spain
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

Rheumatoid Arthritis

Germany
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Tunis University

Completed

0.9% Saline Versus Balanced Solutions in Severe Diabetic Ketoacidosis

Metabolic Ketoacidosis | Ketoacidemia | Acetonemia | Acetonuria

Tunisia
Massachusetts General Hospital
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

Smoking Cessation

United States
Stanford University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Integrating Combined Therapies for Persons With Co-occurring Disorders (ICT)

Mental Health Disorder | Alcohol Use Disorder

United States
GlaxoSmithKline

No longer available

Compassionate Use for Subcutaneous (SC) Belimumab

Systemic Lupus Erythematosus

United States
GlaxoSmithKline

Completed

Japanese phase1 Study of Belimumab (IV vs SC)

Systemic Lupus Erythematosus

Japan
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Istituto Giannina Gaslini

Recruiting

Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

Nephrotic Syndrome

Italy
Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
Amgen

Completed

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)

Lymphoma, Non-Hodgkin

Italy, Spain, United States, Korea, Republic of, Australia, Georgia, Canada, Japan, Bulgaria, India, Romania, Colombia, Mexico, Czechia, France, Germany, Greece, Israel, Poland, Ukraine
The Lymphoma Academic Research Organisation
CHU de Nancy

Completed

Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients

DLBCL

France, Belgium
Lymphoma Study Association
Association pour le Développement de la Recherche Clinique et Informatique...

Completed

Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

B Cell Lymphoma

France
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Non-Hodgkin's Lymphoma

United States
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

France, United States, Russian Federation, Czech Republic, Australia, United Kingdom, Italy, Brazil, Israel, Poland, Ukraine, Puerto Rico
Gedeon Richter Plc.

Unknown

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Rheumatoid Arthritis
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Lymphoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Wolfson Medical Center

Unknown

Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Advanced Refractory Chronic Lymphocytic Leukemia

Israel
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Richter Syndrome | Refractory Transformed Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Hopital Foch
Ministry of Health, France

Recruiting

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis (RIGA)

IgA Vasculitis

France
NCIC Clinical Trials Group

Completed

Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma (IDEC-C2B8)

Lymphoma

Canada
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative Disorder

United States
Beth Israel Deaconess Medical Center

Terminated

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
University Hospital, Toulouse

Completed

The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (RITAI)

Cryoglobulinemia | Cold Agglutinin Disease | Pemphigus | Auto-immune Thrombocytopenic Purpura | Hemolytic Auto-immune Anaemia

France
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Idiopathic Thrombocytopenic Purpura | Anemia, Hemolytic, Autoimmune

Mexico
Geriatric Oncology Consortium
Tibotec Pharmaceutical Limited

Terminated

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Non-Hodgkin's Lymphoma

United States
University Medical Center Groningen
UMC Utrecht; Erasmus Medical Center

Recruiting

Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate (ICON)

Head and Neck Squamous Cell Carcinoma | Margin Assessment

Netherlands
Eli Lilly and Company

Completed

A Study of Mirikizumab in Healthy Chinese Participants

Healthy

China
Eli Lilly and Company

Completed

A Study of Mirikizumab (LY3074828) in Healthy Participants

Healthy

United States
Bristol-Myers Squibb

Completed

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
University of Nebraska
Biogen

Completed

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

Lymphoma

United States
Jurgen Barth
Sponsor GmbH

Active, not recruiting

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas (MAINTAIN)

Non-Hodgkin's Lymphoma | Lymphocytic Lymphoma | Marginal Zone Lymphomas | Follicular Lymphomas | Immunocytomas | Mantle-Cell Lymphomas

Germany
Incyte Corporation

Withdrawn

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Marginal Zone Lymphoma (MZL) | Follicular Lymphoma ( FL)
Tokyo University
Japan Agency for Medical Research and Development; Zenyaku Kogyo Co., Ltd.

Completed

A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis (DesiReS)

Autoimmune Diseases | Collagen Diseases | Scleroderma, Systemic | Lung Fibrosis | Skin Sclerosis

Japan
Hoffmann-La Roche

Completed

A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

Rheumatoid Arthritis

Germany
Johns Hopkins University

Terminated

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

Kidney Failure

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Germany

Search clinical trials for: Rituximab sc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations